StreetInsider.com News Articles

Form 8-K Tonix Pharmaceuticals For: Sep 22

Tue, 22 Sep 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260922/27087459.html

Tonix adds second Medicare payer deal for fibromyalgia drug Tonmya

Tue, 22 Sep 2026 07:03:35 -0400

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced a second major managed Medicare payer agreement for its fibromyalgia drug Tonmya (cyclobenzaprine HCl sublingual tablets), effective immediately, according to a company statement.

The new agreement adds approximately 21 million Medicare lives, representing 38% of the roughly 55 million Medicare beneficiaries in the U.S. Combined with a previously announced Medicare agreement, Tonmya's Medicare coverage now totals approximately 32 million lives, or 58% of the U.S. Medicare population.

Total commercial and government payer coverage for Tonmya, including Medicaid coverage in nearly all states and agreements with two group purchasing organizations, now reaches approximately 166 million covered

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Tue, 22 Sep 2026 07:00:00 -0400

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.)

Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives)

BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Tue, 22 Sep 2026 07:00:00 -0400

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.)

Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives)

Raymond James Reiterates Strong Buy Rating on Tonix Pharma (TNXP)

Tue, 22 Sep 2026 05:06:41 -0400

Raymond James analyst Tiago Fauth reiterated a Strong Buy rating and $27.00 price target on Tonix Pharma (NASDAQ: TNXP).

The analyst comments "Last Friday (September 18), we hosted Tonix CEO Seth Lederman as part of our CEO Strategy Series to discuss the Tonmya launch, TNX-4800’s development in Lyme prevention, and capital allocation across the pipeline. The discussion was incrementally constructive on the benefits and timing of Tonmya’s payer contracts and expanded sales force. For TNX-4800, Seth emphasized rapid protection as both a potential commercial differentiator and trial-design advantage, while identifying the Lyme attack rate as the primary development uncertainty and a

Form 4 Tonix Pharmaceuticals For: Aug 20 Filed by: BAGGER RICHARD H

Mon, 24 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26964438.html

Form 4 Tonix Pharmaceuticals For: Aug 20 Filed by: BAGGER RICHARD H

Mon, 24 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26964438.html

Tonix Pharma CEO named interim chief medical officer

Tue, 18 Aug 2026 16:01:40 -0400

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its Board of Directors appointed Dr. Seth Lederman, the company's President and Chief Executive Officer, as Interim Chief Medical Officer, effective Aug. 18, 2026.

Dr. Lederman, 69, has served as President, CEO, and Chairman of the Board since October 2011 and will continue in those roles alongside the interim CMO appointment.

According to the company, there are no arrangements or understandings between Dr. Lederman and any other person related to the appointment, and no family relationships exist between Dr. Lederman and any director or executive officer of the company.

Tonix Pharma CEO named interim chief medical officer

Tue, 18 Aug 2026 16:01:40 -0400

Dr. Lederman, 69, has served as President, CEO, and Chairman of the Board since October 2011 and will continue in those roles alongside the interim CMO appointment.

Form 8-K Tonix Pharmaceuticals For: Aug 18

Tue, 18 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26944015.html

Form 8-K Tonix Pharmaceuticals For: Aug 18

Tue, 18 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26944015.html

Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26925248.html

Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26925248.html

Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: AQR CAPITAL MANAGEMENT LLC

Thu, 13 Aug 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26917653.html

Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: AQR CAPITAL MANAGEMENT LLC

Thu, 13 Aug 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26917653.html

Tonix Pharma (TNXP) PT Raised to $27 at Raymond James

Mon, 10 Aug 2026 13:46:07 -0400

Raymond James analyst Tiago Fauth raised the price target on Tonix Pharma (NASDAQ: TNXP) to $27.00 (from $26.00) while maintaining a Strong Buy rating.

The analyst comments "Thoughts on the quarter. In Tonmya’s second full quarter on the market, net sales nearly tripled q/q to $11M, well above the level we identified in our preview (link) as an encouraging signal that the launch was on track and recent payer-access gains were beginning to translate into stronger Rx monetization (albeit from a small base early in the launch). With management highlighting the potential for greater downstream pull-through from recent GPO agreements in

Tonix Pharma (TNXP) PT Raised to $27 at Raymond James

Mon, 10 Aug 2026 13:46:07 -0400

Raymond James analyst Tiago Fauth raised the price target on Tonix Pharma (NASDAQ: TNXP) to $27.00 (from $26.00) while maintaining a Strong Buy rating.

Form 10-Q Tonix Pharmaceuticals For: Jun 30

Mon, 10 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260810/26894834.html

Form 10-Q Tonix Pharmaceuticals For: Jun 30

Mon, 10 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260810/26894834.html

Form 8-K Tonix Pharmaceuticals For: Aug 10

Mon, 10 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26894269.html

Form 8-K Tonix Pharmaceuticals For: Aug 10

Mon, 10 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26894269.html

Tonix Pharma (TNXP) Tops Q2 EPS by 27c

Mon, 10 Aug 2026 07:02:16 -0400

Tonix Pharma (NASDAQ: TNXP) reported Q2 EPS of ($2.44), $0.27 better than the analyst estimate of ($2.71). Revenue for the quarter came in at $13.54 million versus the consensus estimate of $6.96 million.

For earnings history and earnings-related data on Tonix Pharma (TNXP) click here.

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study